Combination Oral Chelation in Adult Patients With Transfusion-dependent Thalassemia and High Iron Burden

被引：9

作者：

Hammond, John ^{[1
]}

Thompson, Alexis A. ^{[4
,5
]}

Fogel, Mark A. ^{[2
]}

Hammond, Katherine ^{[4
]}

Kokroko, Jolene ^{[1
]}

Kwiatkowski, Janet L. ^{[1
,3
]}

机构：

[1] Childrens Hosp Philadelphia, Div Hematol, 3401 Civ Ctr Blvd, Philadelphia, PA 19104 USA

[2] Childrens Hosp Philadelphia, Div Cardiol, 34th St & Civic Ctr Blvd, Philadelphia, PA 19104 USA

[3] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA

[4] Ann & Robert H Lurie Childrens Hosp Chicago, Div Hematol Oncol, Chicago, IL 60611 USA

[5] Northwestern Univ, Dept Pediat, Feinberg Sch Med, Chicago, IL 60611 USA

来源：

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY | 2019年 / 41卷 / 01期

关键词：

thalassemia; iron overload; deferasirox; deferiprone; MYOCARDIAL IRON; DEFERIPRONE THERAPY; DEFERASIROX; SAFETY; DEFEROXAMINE; TRIAL; RISK;

D O I：

10.1097/MPH.0000000000001269

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

An open-label, pilot study was conducted to evaluate deferasirox/deferiprone combination chelation therapy in adult patients with transfusion-dependent thalassemia and severe iron overload. Enrollment proved difficult. Nine patients (median age, 27.4 y; ferritin, 4965 ng/mL; liver iron concentration, 28.5 mg/g dry weight; cardiac T2*, 13.3 ms) received treatment. Two were withdrawn for treatment-related adverse effects. Arthralgia (4 patients) and gastrointestinal symptoms (5 patients) were common; no episodes of neutropenia/agranulocytosis occurred. Adherence difficulties were common. Of 6 patients with 12 to 18 months follow-up, 3 showed improvement in cardiac T2* and 2 in liver iron. Combination oral chelation may be effective but adverse effects and adherence challenges may limit efficacy.

引用

页码：E47 / E50

页数：4

共 50 条

[11] INTENSIVE IRON CHELATION IN TRANSFUSION-DEPENDENT THALASSEMIA - EFFECT OF AGE AND PREVIOUS IRON LOADING
PIPPARD, MJ
CLINICAL SCIENCE AND MOLECULAR MEDICINE, 1978, 54 (02): : P2 - P3
[12] Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review
Delea, Thomas E.
Edelsberg, John
Sofrygin, Oleg
Thomas, Simu K.
Baladi, Jean-Francois
Phatak, Pradyumna D.
Coates, Thomas D.
TRANSFUSION, 2007, 47 (10) : 1919 - 1929
[13] ECONOMIC BURDEN OF TRANSFUSION-DEPENDENT CHINESE ADULT -THALASSEMIA PATIENTS FROM SOCIAL PERSPECTIVE
Jia, Y.
Zhen, X.
Wang, Z.
VALUE IN HEALTH, 2022, 25 (07) : S392 - S392
[14] COMBINED CHELATION THERAPY WITH DEFERASIROX AND DEFEROXAMINE IN TRANSFUSION-DEPENDENT PATIENTS WITH THALASSEMIA
Ladis, V.
Delaporta, P.
Kyriakopoulou, D.
Kattamis, A.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 703 - 703
[15] Reducing the iron burden and improving survival in transfusion-dependent thalassemia patients: current perspectives
Bayanzay, Karim
Alzoebie, Lama
JOURNAL OF BLOOD MEDICINE, 2016, 7 : 159 - 169
[16] Iron overload in transfusion-dependent thalassemia
Saliba, Antoine
Taher, Ali
HEMATOLOGY, 2015, 20 (05) : 311 - 312
[17] Real-world experience with iron chelation therapy in transfusion-dependent thalassemia: impact of the oral chelators' era
Pines, Morgan
Kleinert, Dorothy
Thomas, Charlene
Mensah, Cheryl
Musallam, Khaled M.
Sheth, Sujit
ANNALS OF HEMATOLOGY, 2024, 103 (12) : 5229 - 5234
[18] Use of deferiprone for iron chelation in patients with transfusion-dependent thalassaemia
Jamuar, Saumya Shekhar
Lai, Angeline Hwei Meeng
Tan, Ah Moy
Chan, Mei Yoke
Tan, Ee Shien
Ng, Ivy Swee Lian
JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 2011, 47 (11) : 812 - 817
[19] Iron chelation therapy in patients with transfusion-dependent myelodysplastic syndrome
Mast, Alan E.
Field, Joshua J.
TRANSFUSION, 2012, 52 (10) : 2078 - 2080
[20] Iron chelation therapy for children with transfusion-dependent β-thalassemia: How young is too young?
Forni, Gian Luca
Kattamis, Antonis
Kuo, Kevin H. M.
Maggio, Aurelio
Sheth, Sujit
Taher, Ali T.
Viprakasit, Vip
PEDIATRIC BLOOD & CANCER, 2024, 71 (08)

← 1 2 3 4 5 →